

A phase II, double blind, randomised, dose ranging, safety and efficacy trial of rapid intravenous infusion of Zoledronate versus Aredia in breast cancer patients with osteolytic metastases

Submission date 19/08/2002	Recruitment status No longer recruiting	☐ Prospectively registered ☐ Protocol
Registration date 19/08/2002	Overall study status Completed	☐ Statistical analysis plan ☐ Results
Last Edited 09/12/2019	Condition category Cancer	☐ Individual participant data ☐ Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr - -

Contact details
UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA

Additional identifiers

Protocol serial number
C120

Study information

Scientific Title

A phase II, double blind, randomised, dose ranging, safety and efficacy trial of rapid intravenous infusion of Zoledronate versus Aredia in breast cancer patients with osteolytic metastases

Study objectives

Not provided at time of registration

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Primary study design

Interventional

Study design

Randomised controlled trial

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Breast cancer

Interventions

All patients receive treatment for 9 months.

Patients are randomised to one of four treatment groups:

1. Group A: Zoledronate 0.4 mg in 50 ml normal saline rapid infusion every 4 weeks followed by 250 ml 0.9% normal saline 2 h infusion every 4 weeks.
2. Group B: Zoledronate 2 mg in 50 ml normal saline rapid infusion every 4 weeks followed by 250 ml 0.9% normal saline 2 h infusion every 4 weeks.
3. Group C: Zoledronate 4 mg in 50 ml normal saline rapid infusion every 4 weeks followed by 250 ml 0.9% normal saline 2 h infusion every 4 weeks.
4. Group D: Normal saline, 50 ml rapid infusion every 4 weeks followed by 90 mg Aredia (pamidronate) in 250 ml normal saline 2 h infusion every 4 weeks.

Intervention Type

Drug

Phase

Phase II

Drug/device/biological/vaccine name(s)

Zoledronate, Aredia

Primary outcome(s)

Not provided at time of registration

Key secondary outcome(s)

Not provided at time of registration

Completion date

31/01/1998

Eligibility**Key inclusion criteria**

1. Aged >18 years
2. Histologically confirmed diagnosis of breast cancer
3. At least one osteolytic lesion which measures at least 1 cm in diameter which has not been treated with radiation therapy in the 3 months prior to the start of treatment
4. Metastatic bone lesions confirmed by plain films
5. Life expectancy of at least 10 months
6. Performance status (Eastern Cooperative Oncology Group [ECOG]) of 1-2
7. Satisfactory haematological and blood chemistry values
8. No previous continuous treatment (> four doses) with a bisphosphate, or treatment with a bisphosphate within 3 months of the start of treatment. Treatment with another bisphosphate is not allowed at any time during the trial.
9. Patients for whom orthopaedic surgery to bone or radiation therapy to bone is currently scheduled to treat skeletal disease related to metastatic bone lesions may not enter the trial. A previous history of such procedures is permitted only if the procedure was completed more than 2 weeks prior to the start of treatment
10. Patients who develop hypercalcaemia may be treated with a standard therapy other than a bisphosphate and remain on the trial
11. No recent treatment with calcitonin, mitharmycin or gallium nitrate
12. No previous history of allergic reactions or sensitivity to bisphosphates
13. Normal electrocardiogram (ECG)

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 Years

Sex

Female

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/01/1995

Date of final enrolment

31/01/1998

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

MRC Clinical Trials Unit

London

United Kingdom

NW1 2DA

Sponsor information

Organisation

Cancer Research UK (CRUK) (UK)

ROR

<https://ror.org/054225q67>

Funder(s)

Funder type

Charity

Funder Name

Cancer Research UK

Alternative Name(s)

CR_UK, Cancer Research UK - London, Cancer Research UK (CRUK), CRUK

Funding Body Type

Private sector organisation

Funding Body Subtype

Other non-profit organizations

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary